Trends and Clinical Practice Patterns of Sacral Neuromodulation for Overactive Bladder
Dean S Elterman, Bilal Chughtai, Emily Vertosick, Dominique Thomas, James Eastham, Jaspreet Sandhu, Dean S Elterman, Bilal Chughtai, Emily Vertosick, Dominique Thomas, James Eastham, Jaspreet Sandhu
Abstract
Objectives: The aim of this study was to investigate surgical practice patterns of American urologists treating refractory overactive bladder (OAB) over the past decade. Refractory OAB remains a management challenge to urologists. When multiple medical therapies have failed, treatment options may include sacral neuromodulation (SNM) or surgery such as augmentation cystoplasty (AC).
Methods: Data on SNM and AC performed between 2003 and 2012 by certifying and recertifying urologists were obtained in the form of annualized case logs from the American Board of Urology (ABU). Associations between surgeon characteristics (type of certification, annual volume, practice type, and location) and these procedures were evaluated.
Results: Over the past decade, 756 of 6355 urologists certified with the ABU performed SNM or AC for the treatment of refractory OAB. Forty-five (6%) of these surgeons completed fellowships in female urology and 71 surgeons (9%) completed another type of fellowship program. Surgeons recertifying with ABU performed 76% of all SNM procedures. Although SNM and AC have increased from 64 to 2086 between 2003 and 2012, however, this is mainly driven by the increase of SNM from 48 to 2068 cases. Rates of AC have remained stable with 14 to 38 cases reported annually. However, they have declined relative to the total, from 25% in 2003 to less than 1% in 2012.
Conclusions: Sacral neuromodulation has increased dramatically over the past decade in surgeons certified with the ABU. This is in contrast to AC, which while remaining stable in number of procedures.
Conflict of interest statement
Conflict of Interest Statement:
The authors have no conflict of interests to disclose.
Figures
References
- Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology. 2002;60(5 Suppl 1):7–12; discussion 12.
- Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–1087.
- Jayarajan J, Radomski SB. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Research and reports in urology. 2014;6:1–16.
- Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2012;189(4):1388–1395.
- Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455–2463.
- Poon SA, Silberstein JL, Savage C, Maschino AC, Lowrance WT, Sandhu JS. Surgical practice patterns for male urinary incontinence: analysis of case logs from certifying American urologists. J Urol. 2012;188(1):205–210.
- Silberstein JL, Poon SA, Maschino AC, et al. Urinary diversion practice patterns among certifying American urologists. J Urol. 2012;189(3):1042–1047.
- Suskind AM, Dunn RL, Kaufman SR, et al. Understanding the dissemination of sacral neuromodulation. Surgical innovation. 2013;20(6):625–630.
- Chai TC, Mamo GJ. Modified techniques of S3 foramen localization and lead implantation in S3 neuromodulation. Urology. 2001;58(5):786–790.
- Cameron AP, Anger JT, Madison R, Saigal CS, Clemens JQ. National trends in the usage and success of sacral nerve test stimulation. J Urol. 2011;185(3):970–975.
- Cameron AP, Anger JT, Madison R, Saigal CS, Clemens JQ. Battery explantation after sacral neuromodulation in the Medicare population. Neurourol Urodyn. 2012;32(3):238–241.
Source: PubMed